Protein aggregation serves as a critical instability signal, posing a threat to protein function. Detecting this aggregation early in drug development is vital for informed decision-making.
 
In this study, pressure-induced aggregation, avoiding temperature or solvent alterations, was employed. Microfluidic Modulation Spectroscopy (MMS) excels in early detection by measuring minute changes in intermolecular beta-sheet composition - a key indicator of irreversible aggregation.
 
Aurora utilizes a high-power quantum cascade laser (QCL), ensuring unparalleled sensitivity in secondary structure determination across a broad concentration range. Monitoring stability through MMS facilitates correlating drug development conditions to potential adverse effects on protein function at all stages of the development process.